RU2584688C2 - Синтез и противораковая активность производных арил и гетероарилхинолинов - Google Patents

Синтез и противораковая активность производных арил и гетероарилхинолинов Download PDF

Info

Publication number
RU2584688C2
RU2584688C2 RU2013105151/04A RU2013105151A RU2584688C2 RU 2584688 C2 RU2584688 C2 RU 2584688C2 RU 2013105151/04 A RU2013105151/04 A RU 2013105151/04A RU 2013105151 A RU2013105151 A RU 2013105151A RU 2584688 C2 RU2584688 C2 RU 2584688C2
Authority
RU
Russia
Prior art keywords
compound
fluorophenyl
nmr
mhz
methoxyphenyl
Prior art date
Application number
RU2013105151/04A
Other languages
English (en)
Russian (ru)
Other versions
RU2013105151A (ru
Inventor
Шэн-Чу КО
Ко-Хсыун ЛИ
Ли-Цзяу ХУАН
Ли-Чэнь ЧОУ
Тянь-Шун У
Тцзун-Дер ВЭЙ
Цзин-Гун ЧУН
Джей-Сын ЯН
Чи-Хун ХУАН
Мэн-Тун ТСАЙ
Original Assignee
Тэйркс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Тэйркс, Инк. filed Critical Тэйркс, Инк.
Publication of RU2013105151A publication Critical patent/RU2013105151A/ru
Application granted granted Critical
Publication of RU2584688C2 publication Critical patent/RU2584688C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/60—Quinoline or hydrogenated quinoline ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
RU2013105151/04A 2010-07-15 2011-07-14 Синтез и противораковая активность производных арил и гетероарилхинолинов RU2584688C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36476010P 2010-07-15 2010-07-15
US61/364,760 2010-07-15
PCT/US2011/043985 WO2012009519A1 (en) 2010-07-15 2011-07-14 Synthesis and anticancer activity of aryl and heteroaryl-quinolin derivatives

Publications (2)

Publication Number Publication Date
RU2013105151A RU2013105151A (ru) 2014-08-20
RU2584688C2 true RU2584688C2 (ru) 2016-05-20

Family

ID=44533096

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2013105151/04A RU2584688C2 (ru) 2010-07-15 2011-07-14 Синтез и противораковая активность производных арил и гетероарилхинолинов

Country Status (11)

Country Link
US (1) US8524740B2 (enExample)
EP (2) EP3112348A1 (enExample)
JP (3) JP2013532634A (enExample)
KR (2) KR20130043194A (enExample)
CN (1) CN103347859B (enExample)
AU (1) AU2011279118B2 (enExample)
BR (1) BR112013000716B1 (enExample)
CA (2) CA2963390C (enExample)
RU (1) RU2584688C2 (enExample)
TW (1) TWI499417B (enExample)
WO (1) WO2012009519A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150370707A1 (en) * 2014-06-24 2015-12-24 Qualcomm Incorporated Disunited shared-information and private-information caches
EP3302488B1 (en) * 2015-06-03 2020-09-30 Tairx, Inc. Novel use of aryl-quinolin derivatives as inhibitors of vasculogenic mimicry
CN108911967A (zh) * 2018-08-03 2018-11-30 上海华堇生物技术有限责任公司 2,5–二甲氧基苯甲酰氯的制备方法
CN112358462B (zh) * 2020-11-10 2023-11-10 成都伊诺达博医药科技有限公司 一种胡椒环衍生物的合成方法
SMT202500447T1 (it) 2021-11-02 2026-01-12 Flare Therapeutics Inc Agonisti inversi di pparg e loro usi
JP2025513455A (ja) 2022-04-22 2025-04-24 バーテックス ファーマシューティカルズ インコーポレイテッド 疼痛の治療のためのヘテロアリール化合物
CN116789567B (zh) * 2023-05-18 2026-03-27 福建凯昕药业有限公司 抗血小板减少症药芦曲泊帕中间体及其制备方法
US20250367314A1 (en) * 2024-05-31 2025-12-04 Du-Shieng Chien Linker-payload, an antibody-drug conjugate made thereby and uses thereof
CN120695016B (zh) * 2025-08-29 2025-12-02 北京大学 一种二氢喹啉衍生物在制备预防或治疗脂肪肝产品中的用途

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996010563A1 (en) * 1994-09-30 1996-04-11 The University Of North Carolina At Chapel Hill 2-aryl-4-quinolones as antitumor compounds
WO2002026730A2 (en) * 2000-09-25 2002-04-04 University Of North Carolina At Chapel Hill Fluorinated quinolones as antimitotic and antitumor agents
US20050171138A1 (en) * 2003-02-24 2005-08-04 Kuo-Hsiung Lee Flavone acetic acid analogs and methods of use thereof
RU2004112777A (ru) * 2001-11-01 2005-10-27 Астразенека Аб (Se) Терапевтические хинолоновые соединения с 5-ht-антагонистическими свойствами
WO2008070176A1 (en) * 2006-12-07 2008-06-12 China Medical University Novel hydrophilic derivatives of 2-aryl-4-quinolones as anticancer agents

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994002145A2 (en) 1992-07-22 1994-02-03 Genelabs Technologies, Inc. 2-aryl-4-quinolones as antitumor compounds
JPH0733743A (ja) * 1993-07-22 1995-02-03 Kyorin Pharmaceut Co Ltd ２−アリール−４−キノリノール誘導体
US6897316B2 (en) * 2003-08-08 2005-05-24 China Medical University Substituted 2-phenyl-4-quinolone-3-carboxylic acid compounds and their use as antitumor agents
AU2008345225A1 (en) * 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996010563A1 (en) * 1994-09-30 1996-04-11 The University Of North Carolina At Chapel Hill 2-aryl-4-quinolones as antitumor compounds
WO2002026730A2 (en) * 2000-09-25 2002-04-04 University Of North Carolina At Chapel Hill Fluorinated quinolones as antimitotic and antitumor agents
RU2004112777A (ru) * 2001-11-01 2005-10-27 Астразенека Аб (Se) Терапевтические хинолоновые соединения с 5-ht-антагонистическими свойствами
US20050171138A1 (en) * 2003-02-24 2005-08-04 Kuo-Hsiung Lee Flavone acetic acid analogs and methods of use thereof
WO2008070176A1 (en) * 2006-12-07 2008-06-12 China Medical University Novel hydrophilic derivatives of 2-aryl-4-quinolones as anticancer agents

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Yu-Hsun Chang et al. "Design and Synthesis of 2-(3-Benzo[b]thienyl)-6,7-methylenedioxyquinolin-4-one Analogues as Potent Antitumor Agents that Inhibit Tubulin Assembly" JOURNAL OF MEDICINAL CHEMISTRY, vol.52, N15, 2009, 4883-4891. Leping Li et al. "Antitumor Agents. 150. 2',3',4',5',5,6,7-Substituted 2-Phenyl-4-quinolones and related Compounds: Their Synthesis, Cytotoxicity, and Inhibition of Tubulin Polymerization" JOURNAL OF MEDICINAL CHEMISTRY, vol.37, N8, 1994, 1126-1135. *

Also Published As

Publication number Publication date
JP2017206511A (ja) 2017-11-24
EP2593435A1 (en) 2013-05-22
US20120015908A1 (en) 2012-01-19
AU2011279118A1 (en) 2012-12-20
CA2963390C (en) 2020-02-11
AU2011279118B2 (en) 2014-12-18
CA2805590A1 (en) 2012-01-19
JP2013532634A (ja) 2013-08-19
CN103347859A (zh) 2013-10-09
KR20130043194A (ko) 2013-04-29
WO2012009519A1 (en) 2012-01-19
EP2593435B1 (en) 2016-09-07
EP3112348A1 (en) 2017-01-04
BR112013000716A2 (pt) 2019-10-01
TW201206439A (en) 2012-02-16
US8524740B2 (en) 2013-09-03
CN103347859B (zh) 2015-12-02
JP2016028032A (ja) 2016-02-25
KR101913194B1 (ko) 2018-10-31
CA2805590C (en) 2017-05-16
CA2963390A1 (en) 2012-01-19
TWI499417B (zh) 2015-09-11
KR20170118244A (ko) 2017-10-24
RU2013105151A (ru) 2014-08-20
JP6457584B2 (ja) 2019-01-23
JP6371741B2 (ja) 2018-08-08
BR112013000716B1 (pt) 2021-10-05

Similar Documents

Publication Publication Date Title
JP6457584B2 (ja) アリール及びヘテロアリール−キノリン誘導体の合成及び抗癌活性
RU2498981C2 (ru) 7-пиперидиноалкил-3,4-дигидрохинолоновые производные, обладающие антагонистическим действием на рецептор мсн (меланин-концентрирующего гормона)
EP2915806B1 (en) Quinoline compound and use thereof
KR20100014845A (ko) 심혈관 질환을 예방 및 치료하기 위한 화합물
KR20150000901A (ko) 히스톤 탈아세틸효소(hdacs) 억제제
JP7839786B2 (ja) 新規アミノピリジン及びその癌治療への使用
CA2984974A1 (en) Indenoindole derivatives, pharmaceutically acceptable salts or optical isomers thereof, preparation method for same, and pharmaceutical compositions containing same as active ingredient for preventing or treating viral diseases
WO2021231335A1 (en) Novel intermediates and synthesis for endochin-like quinolone compounds
JP7843116B2 (ja) ２－（５－（４－（２－モルホリノエトキシ）フェニル）ピリジン－２－イル）－ｎ－ベンジルアセトアミドの固体形態
ITMI941494A1 (it) Derivati del fenilcarbammato atti all'impiego come anticolinesterasici
EP1541149A1 (en) Phosphodiesterase inhibitor
JP2016516814A (ja) コンブレタスタチン類似体
CN109280032A (zh) 一种哒嗪酮母核结构的组蛋白去乙酰化酶抑制剂及其制备方法和用途
EP3242881B1 (en) Furoquinolinediones as inhibitors of tdp2
FI96417B (fi) Menetelmä uusien terapeuttisesti käyttökelpoisten isokinoliinijohdannaisten valmistamiseksi
Jaipea et al. STRUCTURAL MODIFICATION OF PIPERINE FROM PIPER NIGRUM L.
WO2014179401A1 (en) 2-arylnaphthyridin-4-ones as potent antitumor agents targeting tumorigenic cell lines
KR20100097940A (ko) 신규 ｃｋ2 저해제 및 그의 제조 방법